CoTherix in-licenses hypertension compound

Asahi Kasei (Tokyo, Japan) granted CTRX exclusive North American and European rights to develop and commercialize oral and inhaled formulations of fasudil to treat pulmonary arterial hypertension (PAH). CTRX also received rights to develop and commercialize oral formulations of the Rho kinase inhibitor to treat stable angina in the same territories. Asahi Kasei will receive an $8.8 million upfront payment and is eligible for milestones and royalties. CTRX also received an option to pursue other indications, excluding stroke and eye diseases. ...